Midgard Science

Labs / ADME, DMPK & toxicology

AT

Artery Therapeutics

San Ramon, CA, United States · arterytx.com

GLP

Artery Therapeutics is a clinical-stage biotechnology company developing CS6253, an ABCA1 agonist for APOE4-associated Alzheimer’s disease. It is headquartered in San Ramon, California, and is advancing the program through clinical development for APOE4 homozygous carriers with MCI-Alzheimer’s disease.

They take quote requests by email.

What they offer

  • Drug development for ABCA1-targeted therapies

    Develops first-in-class peptide therapies that target ABCA1 to correct lipid transport defects implicated in disease.

  • Clinical development of CS6253

    Advances CS6253 through clinical trials, including Phase 1 completion and Phase 2A planning.

  • Preclinical pharmacology

    Conducts pharmacology studies supporting candidate selection and mechanism-of-action work in disease models.

  • IND-enabling studies

    Performs GLP toxicology and other studies to support Investigational New Drug filing.

  • CMC development

    Carries out chemistry, manufacturing, and controls activities for the program.

  • Chronic toxicology studies

    Runs long-term GLP toxicology studies to support later-stage clinical development.

What they work on

Modalities
Small molecule, Peptide
Species and models
APOE4 mouse models, primate
Assays and studies
GLP toxicology, pharmacology studies, PK studies, amyloid-β mobilization
Scale and capacity
9-month GLP primate study
Therapeutic areas
Alzheimer's disease, neurodegenerative diseases, metabolic diseases, cardiovascular diseases
Sites
San Ramon, United States
Quality
GLP (toxicology)
Founded
2004

Similar labs. Veloxity Labs, Aurigene Pharmaceutical Services, HitGen, MedChem Partners

Found in a contract services directory. Listing built from arterytx.com. Work here? Claim this listing.

Artery Therapeutics · Midgard Science